Experimental immune cell therapy targets stubborn leukemia
NCT ID NCT05712278
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 27 times
Summary
This early-phase study tested a new treatment for adults with acute myeloid leukemia that returned or didn't respond to standard therapy. The treatment used donated natural killer (NK) cells, a type of immune cell, given after chemotherapy. The main goals were to find a safe dose and check for side effects. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Albert Einstein College of Medicine Site Number : 8400001
The Bronx, New York, 10461, United States
-
University of Nebraska Medical Center Site Number : 8400003
Omaha, Nebraska, 68198-2168, United States
-
~MD Anderson Cancer Center Site Number : 8400002
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.